Skip to main content

Generics

  • Valeant, Biovail become one

    MISSISSAUGA, Ontario The merger between Valeant Pharmaceuticals International and Biovail is complete, the two companies said Tuesday.

     

    Shareholders of both companies have approved the merger, worth more than $3 billion, originally announced in June.

     

     

    The combined company will take Valeant’s name.

     

  • Sun Pharma gets FDA approval for ALS generic

    MUMBAI, India The Food and Drug Administration has approved a generic version of a drug for a devastating muscular disorder.

     

    Sun Pharmaceutical Industries announced Tuesday the approval of riluzole hydrochloride in the 50-mg strength. The tablets are used to treat amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease.

     

     

    The drug is a generic version of Sanofi-Aventis’ Rilutek, which has sales of around $50 million, according to Sun.

     

  • Q&A: A dose of generic Meda-cine

    Many generic drug companies have long marketed branded drugs on the side, but lately, some branded drug companies have sought to enter the generics business as well. One of those companies is Meda Pharmaceuticals, the U.S. subsidiary of Swedish drug maker Meda AB. Drug Store News recently interviewed John White, Meda’s senior director of marketing.

    Drug Store News: What gave Meda the idea of pursuing generics?

  • Hi-Tech Pharmacal to market generic Subutex

    AMITYVILLE, N.Y. Hi-Tech Pharmacal will market a generic version of a drug used to treat opioid dependence, the company said Monday.

     

    Hi-Tech announced that it would market buprenorphine hydrochloride in the 2-mg and 8-mg strengths through its Midlothian Labs division. The drug is in the form of a tablet placed under the tongue.

     

     

    The tablets are a generic version of Reckitt Benckiser’s Subutex, which had sales of $75 million during the 12-month period ended in June, according to IMS Health.

     

  • Perrigo seeks approval for generic Zegerid OTC, Schering-Plough files suit

    ALLEGAN, Mich. Perrigo has filed for regulatory approval of a generic version of an over-the-counter medication for frequent heartburn, prompting a lawsuit from the branded version’s manufacturer.

    The company announced Friday that it had filed for approval for omeprazole and sodium bicarbonate in the 20 mg/1,100 mg strength. The medication is a generic version of Zegerid OTC, made by Schering-Plough HealthCare, a subsidiary of Merck.

     

  • Teva sues Mylan for patent infringement over Copaxone

    JERUSALEM Teva filed a complaint against a generic drug maker this week, asserting four patents for its multiple sclerosis drug are being infringed.

  • Court blocks Apotex's generic Paxil CR

    PITTSBURGH A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions of an antidepressant drug.

     

    Generic drug maker Mylan said Tuesday that it had obtained a temporary restraining order from the U.S. District Court for the District of New Jersey prohibiting Apotex from selling generic versions of the drug Paxil CR (paroxetine hydrochloride), an extended-release formulation of GlaxoSmithKline’s Paxil.

     

     

  • Mylan receives FDA approval for generic Prograf

    PITTSBURGH The Food and Drug Administration has approved a generic treatment for organ transplant patients.

     

    Mylan announced Tuesday the approval of tacrolimus capsules in the 0.5-mg, 1-mg and 5-mg strengths, and said it plans to launch the drug immediately. The drug is used to prevent rejection of transplanted organs.

     

     

X
This ad will auto-close in 10 seconds